

Thank you for completing the Translational Advances in Cancer Prevention Agent Development Meeting Survey program!

OMB No. 0925-0642  
Expiration Date: 03/31/2023

Public reporting burden for this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0642). Do not return the completed form to this address.

Please reflect on your experience in the Translational Advances in Cancer Prevention Agent Development Program.

This survey should take approximately 15 minutes to complete.

**Translational Advances in Cancer Prevention Agent**  
**Development**  
**August 27-29, 2020**  
**MEETING SURVEY**

|  | Excellent | Very Good | Good | Fair | Poor |
|--|-----------|-----------|------|------|------|
| How did the meeting meet your expectations?<br>(Check one box) |           |           |      |      |      |
|  |           |           |      |      |      |

Comments:

| <b>Please rank the following meeting elements:</b>               |           |           |      |      |      |
|--|-----------|-----------|------|------|------|
|  | Excellent | Very Good | Good | Fair | Poor |
| Website  |           |           |      |      |      |
| Registration Process   |           |           |      |      |      |
| Poster Session   |           |           |      |      |      |
| Demonstrations   |           |           |      |      |      |
| Venue  |           |           |      |      |      |
| Hotel  |           |           |      |      |      |
|  |           |           |      |      |      |
| <b>Scientific Sessions:</b>                                      |           |           |      |      |      |
| Plenary Sessions   |           |           |      |      |      |
| Advances in Small Molecule Agent Development                     |           |           |      |      |      |
| Advances in Immunomodulatory Agent Development                   |           |           |      |      |      |
| Alternative Dosing and Combination Strategies to Reduce Toxicity |           |           |      |      |      |
| Emerging Vaccines for Cancer Prevention                          |           |           |      |      |      |
| Cancer Prevention Clinical Trials                                |           |           |      |      |      |

**Comments:**

**What topics would you like to have addressed in next year's program?**

**Comments / Thoughts? (continue on back page if needed)**

|  |  |  |  |  |  |
|--|--|--|--|--|--|
| <b>NCI Information Sessions:</b>                                     |  |  |  |  |  |
| NCI PREVENT Preclinical Drug Development Program                     |  |  |  |  |  |
| Overview of the Cancer Prevention Clinical Trials Network (CP-CTNet) |  |  |  |  |  |

**Comments / Thoughts?**

**If this meeting was scheduled to occur on a regular basis once every 2 years, how likely is it that you would plan on attending regularly?**

\_\_\_\_\_ Definitely

\_\_\_\_\_ Likely

\_\_\_\_\_ Unlikely

**Comments / Thoughts?**